|Year : 2016 | Volume
| Issue : 1 | Page : 123-124
Evaluation of the antibiotic resistance of Pseudomonas aeruginosa isolates according to the changing guidelines
K Yanik1, Y Tanriverdi Cayci1, A Karadag1, S Esen2, M Gunaydin3
1 Department of Medical Microbiology, Faculty of Medical, Ondokuz Mayis University, Samsun, Turkey
2 Department of Infectious Diseases, Faculty of Medical , Ondokuz Mayis University, Samsun, Turkey
3 Department of Medical Microbiology, Faculty of Medical, Istanbul University, Istanbul, Turkey
|Date of Submission||30-Oct-2014|
|Date of Acceptance||06-May-2015|
|Date of Web Publication||15-Jan-2016|
Y Tanriverdi Cayci
Department of Medical Microbiology, Faculty of Medical, Ondokuz Mayis University, Samsun
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Yanik K, Cayci Y T, Karadag A, Esen S, Gunaydin M. Evaluation of the antibiotic resistance of Pseudomonas aeruginosa isolates according to the changing guidelines. Indian J Med Microbiol 2016;34:123-4
|How to cite this URL:|
Yanik K, Cayci Y T, Karadag A, Esen S, Gunaydin M. Evaluation of the antibiotic resistance of Pseudomonas aeruginosa isolates according to the changing guidelines. Indian J Med Microbiol [serial online] 2016 [cited 2020 Apr 8];34:123-4. Available from: http://www.ijmm.org/text.asp?2016/34/1/123/174107
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that commonly found in nature. Resistance to antibiotics and disinfectants is a problem in healthcare settings  some regulations are made in susceptibility testing and interpretation of results. Clinical and Laboratory Standards Institute (CLSI) guideline changed the minimum inhibitory concentrations (MICs) of piperacillin, piperacillin tazobactam, imipenem and meropenem which are used in the treatment of Pseudomonas infections, in 2012.
The aim of this study was; evaluating MIC values of P. aeruginosa isolates which were isolated from clinical specimens according to the CLSI 2011. CLSI 2012 and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines, to reveal differences in susceptibility rates and to contribute to the debate on guide exchange.
A total of 3632 strains for imipenem, 3706 strains for meropenem, 3479 strains for piperacillin and 4760 strains for piperacillin-tazobactam were enrolled in this study. Identification of the strains and MIC values have been studied in Phoenix (BD Diagnostic, ABD) and Vitek2 (Biomerieux, France) automated systems.
When compared CLSI 2011 and 2012 criteria, it was observed that the rate of imipenem-susceptible strains were decreased from 58% to 54 5% and the rate of intermediate strains were increased from 4% to 7 5%. Furthermore, similar changes have been seen for meropenem and 4% decrease was observed for susceptible strains. However, 10% decrease was determined for the rate of susceptible strains for piperacillin and piperacillin-tazobactam [Table 1]. According to EUCAST criteria, while MIC values for imipenem is similar to CLSI 2011, susceptible strain rate same with CLSI 2011 and it was determined to be higher according to CLSI 2012. MIC values in EUCAST for piperacillin and piperacillin-tazobactam is lower and the susceptibility MIC value is same with CLSI 2012.
|Table 1: Comparing of antibiotics which changes have been made in Pseudomonas aeruginosa MIC values and MIC results|
Click here to view
| ~ References|| |
Erdem B. Pseudomonaslar. In: Mutlu G, Emir T, Cengiz AT, Ustacelebi S, Tumbay E, Mete O, editors. Basic and Clinical Microbiology, Ankara, Gunes Publishing; 1999. p. 733-8.
Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa
. J R SocMed 2002;95 Suppl 41:22-6.
Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-second international supplement, M100-S22. Wayne, PA: CLSI; 2012.
Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-second international supplement, M100-S21. Wayne, PA: CLSI; 2011.